We expect Amgen AMGN to beat expectations when it reports second-quarter 2026 results on Aug. 4 after market close. In the last reported quarter, the company's earnings beat expectations by 8.88%. The Zacks Consensus Estimate for second-quarter sales and earnings is pegged at $9.45 billion and $5.60 per share, respectively.Factors to Consider for AmgenIn the second quarter, Amgen’s product sales are expected to have been driven by strong volume growth of products like Repatha, Tezspire, Uplizna and Evenity, among others. However, price declines for some products and increases in 340B program utilization are likely to have offset some of the gains from volume increases.The Zacks Consensus Estimate for Repatha, Tezspire, Uplizna and Evenity sales is pegged at $907.0 million, $483.0 million, $306 million and $636.0 million, respectively.Sales of key drugs, Prolia and Xgeva, are likely to have declined as they have lost patent exclusivity.Patents for Prolia and Xgeva expired in February 2025 in the United States, while the same expired in some European countries in November 2025. The erosion in their sales was in line with expectations in the first quarter. Accelerated sales erosion is expected over the remainder of 2026 as several biosimilars have been launched globally. The Zacks Consensus Estimate for Prolia and Xgeva is pegged at $728.0 million and $356.0 million, respectively.Sales of some other drugs like Kyprolis, Vectibix, Nplate and Lumakras/Lumykras are likely to have risen in the quarter. Sales of new cancer drug Imdelltra (tarlatamab) are likely to have risen sequentially, driven by volume growth. The drug was approved by the name of Imdylltra in the EU in June.In Amgen’s inflammation portfolio, Enbrel sales are likely to have declined due to declining prices. Otezla sales are likely to have been hurt by lower pricing in the United States and generic erosion in the EU.The Zacks Consensus Estimate for Otezla is $562.0 million, while that for Enbrel is $466.0 million.Amgen’s new biosimilar products like a biosimilar version of J&J’s Stelara called Wezlana and Regeneron’s REGN Eylea called Pavblu are also likely to have contributed to sales growth like the past few quarters. Wezlana’s sales are expected mostly from ex-U.S. markets while Pavblu’s sales are expected to have risen sequentially, driven by volume growth.Lower revenues from oncology biosimilars (Kanjinti and Mvasi) due to increased competitive pressure are expected to have hurt the top line. Sales of legacy established products are also expected to have declined.In the second quarter, adjusted operating margin is expected to be in line with the first-quarter operating margin of 45.3%.Investors will look for updates on Amgen’s important pipeline candidate, MariTide (maridebart cafraglutide), a GIPR/GLP-1 receptor for obesity, on the second-quarter conference call.AMGN’s Earnings Surprise HistoryThis large biotech’s performance has been strong, with earnings beating estimates in the trailing four quarters. The company delivered a four-quarter earnings surprise of 11.82%, on average.Amgen’s stock has risen 18.4% so far this year compared with an increase of 2.8% for the industry.Image Source: Zacks Investment ResearchWhat Our Model Says for AMGNOur proven model predicts an earnings beat for Amgen this time around. The combination of a positive Earnings ESPand a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat, which is the case here.Earnings ESP: Amgen’s Earnings ESP is +0.70%. The Zacks Consensus Estimate is pegged at $5.60 per share, while the Most Accurate Estimate is pegged higher at $5.64 per share. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.Zacks Rank: Amgen has a Zacks Rank #3.Other Stocks to ConsiderHere are two drug/biotech stocks that also have the right combination of elements to beat on earnings this time around:Jazz Pharmaceuticals JAZZ has an Earnings ESP of +0.41% and a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.Jazz stock has risen 52% so far this year. JAZZ beat estimates in three of the last four quarters while missing in one. The company has a four-quarter earnings surprise of 10.73%, on average. Jazz is scheduled to report second-quarter results on Aug. 3.Pfizer PFE has an Earnings ESP of +2.07% and a Zacks Rank #3 at present.Shares of Pfizer have risen 0.1% so far this year. Pfizer beat earnings estimates in each of the last four reported quarters, delivering an average earnings surprise of 21.93%. Pfizer is scheduled to report second-quarter results on Aug. 4. Zacks' Research Chief Names "Stock Most Likely to Double" Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest. This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.Free: See Our Top Stock And 4 Runners UpThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment Research

Los Angeles Mayor Karen Bass on Friday signed an emergency executive order restricting Lineage Logistics' ability to rebuild its Boyle Heights food warehouse from the ashes of last month's fire. The order directs city departments to halt processing any requests related to the 500,000 square-foot warehouse pending an investigation into the property and its future [...]

GE Aerospace GE and Northrop Grumman Corporation NOC are two familiar names operating in the aerospace and defense industry. As rivals, both companies are engaged in producing highly engineered aircraft components for commercial and military aircraft in the United States and internationally.Both companies have been enjoying significant growth opportunities in the aerospace and defense space on account of the improving air traffic trend and the expansionary U.S. budgetary policy over the past couple of years. Let’s take a closer look at their fundamentals, growth prospects and challenges.The Case for GE AerospaceGE Aerospace is benefiting from the higher utilization of engine platforms, driven by strong momentum and growth across commercial and defense aerospace sectors. Solid demand for LEAP, GEnx & GE9X engines and services, supported by growth in air traffic, fleet renewal and expansion activities, is driving the performance of the Commercial Engines & Services business.In the first half of 2026, the company secured several major engine orders and service agreements. GE clinched orders from United Airlines and Delta Air Lines to deliver GEnx engines, while it received orders for LEAP engines from American Airlines and Copa Airlines. Copa Airlines selected up to 120 LEAP-1B engines to power its expanding Boeing 737 MAX fleet. It also entered into a long-term materials agreement to support Ryanair’s fleet of about 2,000 CFM56 and LEAP engines.The company is also making progress under its FLIGHT DECK lean model, including supplier improvements that contributed to Commercial Engines & Services business’ revenues. In the second quarter of 2026, the segment’s engine deliveries increased 26% from the prior-year quarter, indicating better throughput as the company works through customer demand. The Commercial Engines & Services segment’s revenues and orders jumped 27% and 18%, respectively, on a year-over-year basis in the second quarter.Solid demand for the company’s propulsion & additive technologies, critical aircraft systems and aftermarket services in the defense sector is boosting the Defense & Propulsion Technologies business’ performance. GE received a contract from Turkish Aerospace Industries (“TAI”) to continue integrating its F404 engine into Türkiye's Hurjet jet trainer. It also clinched a $1.4 billion deal for T408 engines to support the U.S. Marine Corps’ CH-53K helicopter fleet. In second-quarter 2026, the Defense & Propulsion Technologies segment’s revenues increased 16% year over year and orders grew 12%.The company’s shareholder-friendly policies also add to its appeal. In the first six months of 2026, it paid dividends of $873 million, up 26.9% year over year, to its shareholders. It also raised its dividend by 30.6% to 36 cents per share in February 2026. In the same period, the company repurchased shares for $4.2 billion.The Case for Northrop GrummanNorthrop is expected to continue generating steady organic growth in 2026 and beyond as it continues to win new awards and thereby convert the robust backlog, which was $104.7 billion as of June 30, 2026, into solid sales growth. Such a robust backlog count is backed by increasing demand for the company’s defense products and rising global defense budget support, which in turn should boost Northrop’s revenue-generating prospects substantially.The current U.S. government’s inclination toward strengthening the nation’s defense system should act as a growth catalyst for defense contractors like Northrop. Considering that sales from Northrop to the U.S. government comprised 84% of its total sales in 2025, solid funding provisions from the administration are expected to lead to a solid inflow of contracts for Northrop. Foreign military sales also serve as a key growth catalyst for Northrop. The company’s international sales totaled $1.54 billion in the second quarter of 2026, comprising 14% of total sales. Region-wise, Northrop is witnessing significant opportunities for its Integrated Battle Command System (IBCS) and other weapons in Europe. Moreover, the long-standing conflicts in different parts of the Middle East have also been fueling demand for modern defense products.NOC also remains committed to rewarding its shareholders through dividends and buybacks. In the first six months of 2026, it paid dividends of $684 million, up 7.9% year over year, to its shareholders. It also raised its dividend by 6.9% to $2.47 per share in May 2026. In the same period, the company repurchased shares for $68 million.Despite the positives, NOC’s highly leveraged balance sheet remains concerning. Exiting the second quarter, Northrop’s long-term debt was high at $14.4 billion. Considering the high debt level, its cash and cash equivalents of $2.3 billion do not look impressive.Price PerformanceImage Source: Zacks Investment ResearchIn the past six months, GE Aerospace shares have risen 15%, while Northrop stock has lost 21.9%.The Zacks Consensus Estimate for GE & NOCImage Source: Zacks Investment ResearchThe Zacks Consensus Estimate for GE’s 2026 sales and earnings per share (EPS) implies year-over-year growth of 19.7% and 23.4%, respectively. EPS estimates for both 2026 and 2027 have increased over the past 60 days.Image Source: Zacks Investment ResearchThe Zacks Consensus Estimate for Northrop’s 2026 sales and EPS implies year-over-year growth of 4.9% and 9.5%, respectively. EPS estimates for both 2026 and 2027 have been raised over the past 60 days.Valuation of GE & NorthropImage Source: Zacks Investment ResearchNorthrop is trading at a forward 12-month price-to-earnings ratio of 17.99X, close to its median of 18.74X over the last three years. GE’s forward earnings multiple sits at 41.88X, higher than its median of 37.01X over the same time frame.Final TakeGE Aerospace’s strong momentum in the commercial and defense aerospace markets, driven by solid build rates, wide-body aircraft demand and a robust defense budget, bodes well for growth. Given the strength across most of its served markets, GE has built a sound liquidity position that supports its shareholder-friendly policies.In contrast, Northrop’s strength in the defense aerospace market, along with its robust pipeline of projects, favors well for its growth. Its shareholder-friendly policies add to its appeal. However, this has been marred by the supply-chain challenges and high debt level, which might affect its performance.Despite its steeper valuation, GE holds robust prospects due to strong estimates, stock price appreciation and better prospects for sales and profit growth. Given these factors, GE seems a better pick for investors than Northrop currently. While GE carries a Zacks Rank #2 (Buy), Northrop currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Zacks' Research Chief Names "Stock Most Likely to Double" Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest. This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.Free: See Our Top Stock And 4 Runners UpThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment Research

BONG REVILLA POSTS BAIL, RELEASED FROM DETENTION Former senator Ramon “Bong” Revilla Jr. shared a family photo on Friday, July 31, 2026, after posting a ₱1 million cash bond. The Sandiganbayan granted Revilla’s petition for bail in connection facebook.com

Instagram-Savvy `Cockroaches’ Spur India Pivot in Blow to Modi Bloomberg.com

In a 2016 UCLA fMRI study, teenagers were more likely to like an Instagram photo with a high, researcher-assigned like count than the same photo with a low count, whether the image was ordinary or risky, showing how little the content itself mattered Silicon Canals

International Business Machines Corporation IBM is framing enterprise AI around control, governance and hybrid deployment rather than a pure model race. That positioning fits clients that need AI to work with regulated data, existing infrastructure and mission-critical applications.The key investor question is whether this strategy can turn early AI demand into durable revenue. IBM has visible traction, but revenue conversion remains gradual and the execution bar is rising.IBM Positions Governance at the Center of AIIBM’s AI architecture is built around watsonx Orchestrate, which management describes as a control plane for building, managing and governing AI agents. The platform is designed to work across clouds and on-premises systems, where many large enterprises still keep sensitive data and critical workloads.Concert adds a unified view of application health, security, compliance and operational performance. Together with related tools for observability, evaluation, identity management and security, the strategy addresses enterprise concerns about trust, access control and governance.IBM Turns AI Demand Into Consulting WorkConsulting is where IBM is seeing early evidence that AI projects are moving beyond pilots. Generative AI represented about half of Consulting signings in the second quarter of 2026 and more than 30% of backlog.The monetization path is still measured. Consulting revenues increased only 1% at constant currency, even as signings rose 6% to $5 billion. Segment profit rose 15.1%, and margin expanded 160 basis points to 12.1%, showing that productivity and delivery discipline are helping offset limited top-line growth.IBM Expands AI Security Through LightwellLightwell extends IBM’s AI strategy into open-source security. The platform is designed as an AI-driven clearinghouse for remediated open-source vulnerabilities, a need that has grown as enterprises rely on more external code inside critical systems.IBM has backed Lightwell with a $5 billion commitment. More than 7,500 remediated package versions were available at launch, and clients can subscribe for $1 million per year. Early adopters include major financial institutions such as Bank of America, BNY, Citi, Goldman Sachs, JPMorgan Chase, Mastercard, Morgan Stanley, Royal Bank of Canada, State Street, Visa and Wells Fargo.IBM Uses Partnerships to Broaden AI AdoptionIBM is also using partnerships to extend its reach. Its collaboration with OpenAI focuses on integrating AI into cybersecurity operations, while the expanded ServiceNow Inc. NOW relationship targets fragmented enterprise data and aging legacy systems.Alphabet Inc. GOOGL, through Google Cloud, is another relevant partner as IBM builds a Google Cloud Practice inside Consulting. That relationship combines IBM’s industry expertise and Consulting Advantage platform with Google Cloud’s Gemini Enterprise AI platform, giving IBM a way to participate in production-scale AI deployment without owning every technology layer.IBM’s AI Push Meets a Legacy Disruption RiskAI can also pressure part of IBM’s legacy-services franchise. Tools such as Anthropic’s Claude Code may automate parts of COBOL exploration, documentation, refactoring and security analysis, areas tied to mainframe modernization.That creates a two-sided issue. IBM can use AI to improve delivery and modernize client systems more efficiently, but automation could reduce reliance on specialized legacy-system services if clients adopt alternative tools at scale.IBM’s Scores Signal Caution on the AI ThemeIBM’s enterprise AI strategy is credible, especially for clients that care about governance, cybersecurity and data control. Still, the investment case needs clearer evidence that AI demand can convert into sustained software and consulting revenue growth.The stock currently carries a Zacks Rank #3 (Hold). Its Value Score of C and Growth Score of C suggest neither valuation nor growth stands out strongly, while the Momentum Score of D and VGM Score of D point to weak share-price trends and limited near-term conviction. For now, IBM’s AI story is progressing, but the scores support a measured view rather than an aggressive one.You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Research Chief Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.Free: See Our Top Stock And 4 Runners UpThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment Research

Alaska Air Group ALK is pushing through a costly transition aimed at improving the quality of its revenue base. The strategy centers on premium travel, loyalty growth, long-haul flying and a more modern fleet.The plan could make the combined Alaska and Hawaiian network more durable over time. It also raises execution demands at a point when fuel, leverage and operating complexity remain real constraints.Alaska Air Leans Into Premium DemandAlaska Air’s premium revenue increased 15% in the second quarter, while managed corporate revenue rose 30%. Those gains show demand is shifting toward customers who pay for a better travel experience and broader network access.The company has completed 737 cabin retrofits, adding expanded first and premium class seating. The Hawaiian combination also adds lie-flat seating on select long-haul routes, giving Alaska a stronger premium offer as it competes with Delta Air Lines DAL and United Airlines Holdings UAL for higher-value travelers on global routes.ALK Turns Loyalty Into a Larger Revenue EngineLoyalty is becoming a bigger part of Alaska Air’s revenue mix. Loyalty program other revenue increased 23% in the second quarter, while loyalty cash remuneration rose 19%.Atmos Rewards gives Alaska and Hawaiian a single loyalty platform across a larger customer base. That matters because the combined network now spans more than 140 destinations, giving members more ways to earn, redeem and stay engaged across Alaska and Hawaiian routes.Alaska Air Shifts Growth Toward Long-Haul FlyingFor the third quarter, Alaska Air expects capacity to increase 2% to 3% year over year. Nearly all of that growth is expected to come from long-haul international flights out of Seattle, while North America capacity is expected to remain essentially flat.This mix broadens ALK’s market reach and supports its ambition to build more global relevance from Seattle. It also brings added costs, including crew training tied to the international widebody ramp and the operational complexity of scaling a larger long-haul network.ALK Modernizes Aircraft and ConnectivityFleet modernization remains a central part of the long-term plan. Alaska has extended its Boeing delivery stream through 2035, supporting replacement of older aircraft and measured growth with newer, more fuel-efficient planes.Product upgrades are part of the same strategy. Fleetwide Starlink Wi-Fi installation is expected to be completed by the end of 2027, turning connectivity into both a customer-experience improvement and a point of differentiation.Alaska Air Expands Maintenance InfrastructureAlaska Air is also investing in the maintenance base needed to support a larger and more complex fleet. The company is building a new maintenance hangar at Portland International Airport with an investment of more than $135 million.The facility is expected to be completed in the second quarter of 2028. It will add about 125,000 square feet of indoor aircraft maintenance space and 60,000 square feet for offices, workshops, and support functions, with the capacity to service up to three narrowbody aircraft or two widebody aircraft simultaneously.ALK’s Scores Temper the Trend StoryThe bottom line is that Alaska Air’s strategic direction is clear, but the payoff is not yet clean. Premium revenue, loyalty and international expansion can improve revenue quality, while fleet and maintenance investments can support efficiency and resilience.ALK currently carries a Zacks Rank #3 (Hold). Its Value Score of B suggests the stock has a relatively attractive value profile, especially for investors focused on entry valuation. You can see the complete list of today’s Zacks #1 Rank stocks (Strong Buy) here.On the basis of forward price-to-sales ratio (P/S F12M), shares of ALK trade at a lower multiple compared to its industry.Image Source: Zacks Investment ResearchThe Growth Score of F, Momentum Score of F and VGM Score of D temper that view. Style Scores are designed to complement the Zacks Rank, and the weaker growth and momentum grades signal that Alaska’s strategic trends have not yet translated into a convincing near-term earnings or market momentum setup. Research Chief Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.Free: See Our Top Stock And 4 Runners UpThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment Research

International Business Machines Corporation IBM has pulled back sharply in 2026, raising the question of whether the lower price has improved the risk-reward profile.The answer is mixed. IBM has dividend support, software momentum and free cash flow, but slower growth, estimate pressure and acquisition-related balance sheet risks keep the entry point from looking clearly cheap.IBM’s Valuation Offers Limited Margin for ErrorIBM trades at 17.27 times forward 12-month earnings, slightly above its five-year median of 16.69 times. That is well above the sub-industry’s 10.4 times, although below the broader technology sector’s 20.01 times.That valuation is not distressed despite the stock’s decline. The $244 price target compares with a reported share price of $221.74, implying only measured appreciation rather than a reset that leaves wide room for error.IBM Earnings Growth Remains MeasuredEarnings growth also looks gradual. IBM is expected to generate earnings of $11.85 per share in 2026, up from $11.59 in 2025, with a further rise to $12.69 projected for 2027.The current-year earnings estimate has slipped 0.5% in the past four weeks. A PEG ratio of 4.0 reinforces the concern that investors are paying a meaningful multiple for modest expected growth.IBM Cash Flow Supports the DividendIBM generated $4.8 billion of free cash flow in the first half of 2026 and still expects free cash flow to increase by about $1 billion year over year for the full year.That cash generation supports the dividend, which yields roughly 3%. Recurring software revenue, including annual recurring revenue of $24.6 billion, and productivity actions help fund distributions even as quarterly free cash flow can fluctuate.IBM’s Debt Load Raises the Risk BarThe balance sheet raises the threshold for a buy case. IBM ended the second quarter with $62 billion of debt, while cash, restricted cash and marketable securities declined to $8.2 billion.Goodwill stood at $74.6 billion, and the current ratio was 0.79:1. Those figures reduce flexibility for additional acquisitions, faster dividend growth and other capital priorities, especially after acquisition spending lifted leverage.IBM’s Business Mix Creates Upside and RiskIBM’s portfolio still has attractive pieces. Red Hat revenues grew 11%, Data revenues increased 18% at constant currency and Software remains the company’s largest segment.The offset is volatility elsewhere. IBM Z revenues fell 42%, and Transaction Processing declined 9% at constant currency, showing that infrastructure cycles and deal timing can still weigh on results.Microsoft Corporation MSFT, through Azure Red Hat OpenShift, and Oracle Corporation ORCL, through Oracle Cloud Infrastructure and database-led AI offerings, remain relevant benchmarks for enterprise cloud and AI spending. IBM’s case depends on higher-value software and AI services becoming large enough to absorb that pressure.IBM’s Ratings Point to a Wait-and-See ViewThe bottom line is that IBM’s pullback has improved the share price, but it has not removed the valuation, growth or leverage questions. The stock currently carries a Zacks Rank #3 (Hold), which fits a mixed setup rather than a clear buy signal.IBM has a Value Score of C and Growth Score of C, suggesting balanced but not standout characteristics on those measures. Its Momentum Score of D and VGM Score of D point to weaker share-price trends and limited near-term conviction, even with dividend support and a lower stock price.You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Research Chief Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.Free: See Our Top Stock And 4 Runners UpThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment Research

https://variety.com/2026/tv/news/fox-ispot-measurement-partnership-outcomes-1236823002/

New details were released Friday, including the identities of both suspects and the victim connected to a violent kidnapping that ended with the deaths of the victim and one of the suspects in Chino Hills late Wednesday night. Investigators said 60-year-old Shukur Aikebaer stepped outside his home in the 2100 block of Monteverde Drive around [...]

Elon Musk Surprisingly Doesn't Understand Abundance Bloomberg.com

Technology licensing is evolving well beyond smartphones as connected devices, streaming platforms, artificial intelligence (AI) applications and next-generation wireless networks create new opportunities for intellectual property owners. Companies with broad patent portfolios are increasingly positioned to monetize innovation across multiple industries.InterDigital, Inc. IDCC is embracing this shift by expanding its licensing programs into cloud services, streaming, IoT and emerging communications technologies while continuing to invest in future standards development.How InterDigital Is Expanding Beyond MobileInterDigital has steadily diversified its licensing business beyond traditional handset royalties. While wireless patents remain its core asset, the company now licenses technologies used in streaming services, cloud platforms, consumer electronics, payment terminals, electric vehicle charging equipment and other IoT applications. Recent licensing activity reflects that broader strategy. The company reached a milestone agreement with Amazon covering devices and services, including Prime Video, while also signing IoT agreements with a leading fintech company for payment terminals and with KEBA for EV chargers. These relationships expand recurring licensing opportunities across markets that extend well beyond smartphones. InterDigital, Inc. Price and Consensus InterDigital, Inc. price-consensus-chart | InterDigital, Inc. QuoteCompanies such as QUALCOMM Incorporated QCOM and Dolby Laboratories, Inc. DLB likewise benefit from licensing advanced communications and media technologies, illustrating how intellectual property is becoming increasingly valuable across multiple technology ecosystems.Why IDCC Is Investing in AI and 6GInterDigital continues investing in technologies expected to shape future communications standards. Its research spans artificial intelligence, machine learning, advanced video technologies and 6G networking, all of which support the creation of new patent portfolios that can generate licensing revenue over time. The company also maintains a leadership role in global standards organizations, helping define future wireless specifications while positioning its intellectual property for broad industry adoption. Continued innovation in AI-native networking and advanced video technologies supports licensing opportunities across consumer electronics, industrial applications and connected infrastructure. How InterDigital Strengthens Licensing PowerBeyond research, InterDigital continues to reinforce its negotiating position through both commercial agreements and intellectual property enforcement. The Amazon agreement resolved pending litigation while establishing a framework for determining final licensing terms through binding arbitration. The company also secured two injunctions against Disney from Europe's Unified Patent Court covering video encoding patents across 11 European countries. Combined with new licensing agreements in the IoT market, these developments reinforce the strength of InterDigital's patent portfolio and may improve its position in future licensing negotiations. What Industry Trends Could Challenge IDCCDespite favorable long-term trends, several factors could limit growth. Technology evolves rapidly, requiring continuous investment in research to maintain competitive patent portfolios and relevance within changing wireless standards.The company also faces ongoing intellectual property enforcement costs, while licensing revenue can fluctuate based on agreement timing and arbitration outcomes. In addition, macroeconomic pressures and weaker demand in portions of the consumer electronics and IoT markets could reduce licensing activity or delay customer investments. Customer concentration remains another important consideration for investors evaluating long-term performance. Why IDCC's Ratings Matter for Trend InvestorsInterDigital's strategy aligns with several of the technology industry's fastest-growing themes, including AI, cloud computing, streaming services and connected devices. As these markets expand, the company's diversified licensing model provides additional avenues for recurring royalty growth.The stock currently sports a Zacks Rank #1 (Strong Buy), reflecting favorable earnings estimate momentum. You can see the complete list of today’s Zacks #1 Rank stocks here. However, investors should also consider its Value Score of D, Growth Score of C, Momentum Score of F and VGM Score of F. While the Zacks Rank points to a favorable near-term earnings outlook, the Style Scores indicate that valuation, growth characteristics and recent price momentum remain mixed, providing additional context when evaluating the company's longer-term technology opportunity. Research Chief Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.Free: See Our Top Stock And 4 Runners UpThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment Research

Perfect Corp. (PERF) could be a solid choice for investors given the company's remarkably improving earnings outlook. While the stock has been a strong performer lately, this trend might continue since analysts are still raising their earnings estimates for the company.The upward trend in estimate revisions for this company reflects growing optimism of analysts on its earnings prospects, which should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. Our stock rating tool -- the Zacks Rank -- has this insight at its core.The five-grade Zacks Rank system, which ranges from a Zacks Rank #1 (Strong Buy) to a Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record of outperformance, with Zacks #1 Ranked stocks generating an average annual return of +25% since 2008.For Perfect Corp., there has been strong agreement among the covering analysts in raising earnings estimates, which has helped push consensus estimates considerably higher for the next quarter and full year.The chart below shows the evolution of forward 12-month Zacks Consensus EPS estimate:12 Month EPSCurrent-Quarter Estimate RevisionsThe company is expected to earn $0.02 per share for the current quarter, which represents a year-over-year change of 0.0%.Over the last 30 days, the Zacks Consensus Estimate for PERFECT CORP has increased 50% because one estimate has moved higher compared to no negative revisions.Current-Year Estimate RevisionsFor the full year, the earnings estimate of $0.08 per share represents a change of +60.0% from the year-ago number.The revisions trend for the current year also appears quite promising for PERFECT CORP, with one estimate moving higher over the past month compared to one negative revision. The consensus estimate has also received a boost over this time frame, increasing 32.35%.Favorable Zacks RankThanks to promising estimate revisions, PERFECT CORP currently carries a Zacks Rank #2 (Buy). The Zacks Rank is a tried-and-tested rating tool that helps investors effectively harness the power of earnings estimate revisions and make the right investment decision.You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.Our research shows that stocks with Zacks Rank #1 (Strong Buy) and 2 (Buy) significantly outperform the S&P 500.Bottom LineInvestors have been betting on PERFECT CORP because of its solid estimate revisions, as evident from the stock's 14.2% gain over the past four weeks. As its earnings growth prospects might push the stock higher, you may consider adding it to your portfolio right away. Zacks' Research Chief Names "Stock Most Likely to Double" Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest. This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.Free: See Our Top Stock And 4 Runners UpThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment Research

Agios Pharmaceuticals AGIO reported a loss of $1.69 per share for the second quarter of 2026, narrower than the Zacks Consensus Estimate of a loss of $1.86. In the year-ago quarter, the company had incurred a loss of $1.93 per share.Total revenues for the quarter came in at $44.7 million, significantly beating the Zacks Consensus Estimate of $23 million. Revenues surged 259.3% year over year, primarily driven by continued strong growth in Pyrukynd sales and robust demand for Aqvesme since the U.S. commercial launch in January this year.The company’s lead drug, mitapivat, is marketed under two brand names in the United States, Pyrukynd and Aqvesme. While Pyrukynd is approved for the treatment of hemolytic anemia in adult patients with pyruvate kinase (PK) deficiency, Aqvesme is approved to treat anemia in adults with alpha- or beta-thalassemia.Aqvesme received approval in the United States in December 2025 and was subsequently launched in January 2026, following the implementation of its Risk Evaluation and Mitigation Strategy program. Agios reported a strong initial uptake, with 442 prescriptions written as of June 30, 2026.Outside the United States, mitapivat continues to be marketed as Pyrukynd for PK deficiency and thalassemia indications. In May, Pyrukynd received approval for thalassemia in the European Union. Agios’ partner, Avanzanite Bioscience B.V., will commercialize and distribute Pyrukynd across the European Economic Area, the United Kingdom and Switzerland.AGIO's Q2 Earnings in DetailThe top line entirely comprises product revenues from Pyrukynd and Aqvesme. Agios generated $40.9 million of product revenues in the United States, up 235.2% year over year, driven by strong early momentum of the U.S. commercial launch of Aqvesme for thalassemia.The company added $3.8 million from ex-U.S. territories, driven by anticipated demand for Pyrukynd following its approval for thalassemia in Europe, as well as continued steady early demand across the Gulf Cooperation Council countries.Research and development expenses increased by approximately 9.6% year over year to $100.8 million in the quarter. The increase was primarily driven by the $25.0 million upfront payment related to the licensing agreement with Oscotec for cevidoplenib.Selling, general and administrative expenses totaled $51.5 million, up around 12.4% year over year, driven by higher spending associated with the commercial launch of Aqvesme.As of June 30, 2026, cash, cash equivalents and marketable securities totaled $964.8 million compared with $1.0 billion as of March 31, 2026. Management expects its existing cash balance, together with anticipated product revenues, to be sufficient to support the potential launch of mitapivat in sickle cell disease (SCD) if approved and advance its clinical pipeline.AGIO’s 2026 GuidanceFor full-year 2026, Agios expects to generate $45 million to $50 million in U.S. sales from Pyrukynd for PK deficiency.The company reiterated that full-year operating expenses are expected to remain approximately flat compared with 2025, excluding the $25 million upfront payment related to the cevidoplenib in-licensing agreement recognized in the second quarter.AGIO's Recent Pipeline UpdatesBeyond the marketed indications, Agios is also developing mitapivat for sickle cell disease (SCD). Earlier this month, the FDA accepted its supplemental new drug application (sNDA) seeking approval for mitapivat in SCD. The sNDA was submitted under the FDA’s accelerated approval pathway in May. With the FDA granting a priority review to the sNDA, a decision from the regulatory body is expected on Nov. 1, 2026. If approved, mitapivat is likely to become the first oral PK activator to be approved for patients with SCD.Agios had been developing another candidate, tebapivat, a novel PK activator, for the treatment of lower-risk myelodysplastic syndromes (LR-MDS) and SCD in separate mid-stage studies. However, the company has discontinued the development of tebapivat across all indications following setbacks in the clinical programs.In June, the company halted the candidate's development for LR-MDS after a phase II dose-finding study failed to demonstrate sufficient clinical benefit, despite showing biological activity and a favorable safety profile. Subsequently, in July, Agios also discontinued the SCD program after phase II data failed to demonstrate meaningful clinical differentiation from existing PK activators. These decisions marked the complete termination of the tebapivat development program.Despite the earnings beat, shares of AGIO were down 6.4% on Thursday, likely due to investor concern about the loss of tebapivat as a pipeline asset, which narrowed the company's growth prospects and increased its reliance on mitapivat, with its upcoming FDA decision now serving as the key catalyst.Image Source: Zacks Investment ResearchYear to date, the stock has risen 20.4% compared with the industry’s 3.6% growth.In early June, the company entered into an agreement with Oscotec, a South Korea-based biotech to in-license exclusive global rights to develop and commercialize cevidoplenib for immune thrombocytopenia (ITP).Cevidoplenib is a next-generation, late-stage, highly selective oral spleen tyrosine kinase inhibitor being developed for the treatment of patients with ITP, a rare autoimmune disorder characterized by low platelet counts and an elevated risk of bleeding.The agreement expands and diversifies Agios’ rare hematology portfolio by adding a potential treatment for ITP, with an estimated peak annual U.S. sales potential of up to $1 billion. Agios intends to advance cevidoplenib into a phase III study for ITP, with initiation expected in the first half of 2028. Per the agreement, Agios will fund all future development and commercialization costs associated with cevidoplenib.Agios Pharmaceuticals, Inc. Price, Consensus and EPS Surprise Agios Pharmaceuticals, Inc. price-consensus-eps-surprise-chart | Agios Pharmaceuticals, Inc. QuoteAGIO’s Zacks Rank & Stocks to ConsiderAgios currently carries a Zacks Rank #3 (Hold).Some better-ranked stocks in the biotech sector are Harmony Biosciences HRMY and Liquidia Corporation LQDA, each currently sporting a Zacks Rank #1 (Strong Buy) and Neurocrine Biosciences NBIX, which carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.Over the past 90 days, earnings per share estimates for Harmony Biosciences have decreased from $3.34 to $3.30 for 2026. Over the same period, estimates for earnings per share increased from $3.79 to $3.87 for 2027. HRMY shares have lost 4.2% year to date.Harmony Biosciences missed on earnings in each of the trailing four quarters, delivering an average negative surprise of 25.16%.Over the past 90 days, estimates for Liquidia’s 2026 earnings per share have increased to $3.02 from $1.50. Over the same period, EPS estimates for 2027 have risen to $5.31 from $2.91. LQDA shares have gained 151.7% year to date.Liquidia’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 54.40%.Over the past 90 days, estimates for Neurocrine Biosciences’ 2026 earnings per share have risen from $8.00 to $9.09. Over the same period, EPS estimates for 2027 have increased from $9.48 to $10.81. NBIX shares have gained 30.8% year to date.Neurocrine Biosciences’ earnings beat estimates in three of the trailing four quarters and missed in the remaining one, the average surprise being 9.08%. Zacks' Research Chief Names "Stock Most Likely to Double" Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest. This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.Free: See Our Top Stock And 4 Runners UpThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment Research

https://deadline.com/2026/07/disney-ae-global-media-stake-sale-hearst-1237013578/

Elon Musk’s Fortune Slumps to Pre-SpaceX IPO Levels After Rout Bloomberg Law News

Former Facebook Employee: User Addiction Was Deliberately Engineered. Exclusive.kz